6-K
NEWBiodexa Provides R&D Update on Phase 3 Serenta Trial and MTX240 Program
6-K
Biodexa Announces 100 Patients Enrolled in Phase 3 Trial of eRapa for FAP
6-K
Biodexa Pharmaceuticals PLC Announces ADS Ratio Change
6-K
Biopharmaceutical company secures $2.3 million through warrant exercise, issuing new warrants for future ADS purchases.
6-K
Biodexa Pharmaceuticals PLC Reports Interim Results for the Six Months Ended June 30, 2026
6-K
Biodexa Pharmaceuticals PLC Announces Results of General Meeting and Share Reorganization
